[P129] Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A randomized, open-label, multi-center study

*Qi Liu¹, Qi Wu², Xin Yu³ (1. Peking University Sixth Hospital, 2. Sumitomo Pharma (China) Co., Ltd., 3. Peking University Sixth Hospital )

[P130] Celecoxib added to risperidone for depressive symptoms in first-episode and drug naïve schizophrenia: Pharmacogenetic impact of BDNF gene polymorphisms

*Dongmei Wang^1,2, Xijing Chen^1,2, Yang Tian^1,2, Zhixuan Yu^1,2, Dachun Chen³, Meihong Xiu³, Thomas Kosten^4,5, Xiangyang Zhang^1,2 (1. CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China, 2. Department of Psychology, University of Chinese Academy of Sciences, Beijing, China, 3. Beijing HuiLongGuan Hospital, Peking University, Beijing, China, 4. Mental Health Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA, 5. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA)

[P131] A Real-World Study of Point Of Care Monitoring (POCM) for Clozapine Bloodwork in a Community Setting

*Pierre Chue¹, Moriah Tate², Jonathan Chue³ (1. University of Alberta, 2. Athabasca University, 3. Medical University of Sofia)

[P132] Interim report of a post-marketing surveillance of paliperidone palmitate 3-month formulation in Japanese patients with schizophrenia.

*Tatsuro Marumoto¹, Yosuke Saga¹, Hiroaki Kinoshita², Natsuko Morita², Tokiko Touma³, Shinya Wakamatsu¹, Kyoko Takebe², Akihide Wakamatsu¹, Chih-Lin Chiang¹ (1. Medical Affairs Division, Janssen Pharmaceutical K.K., 2. Drug Safety Surveillance Department, Japan Safety & Surveillance Division, Janssen Pharmaceutical K.K., 3. Statistics & Decision Sciences Japan, Janssen Pharmaceutical K.K.)

[P133] Factors associated with continuation of paliperidone palmitate 1-month formulation monotherapy in patients with schizophrenia.

*Tatsuro Marumoto¹, Hiroshi Horio¹, Hiroaki Kinoshita², Natsuko Morita², Tokiko Touma³, Kyoko Takebe², Akihide Wakamatsu¹ (1. Medical Affairs Division, Janssen Pharmaceutical K.K., 2. Drug Safety Surveillance Department, Japan Safety & Surveillance Division, Janssen Pharmaceutical K.K., 3. Statistics & Decision Sciences Japan, Janssen Pharmaceutical K.K.)

[P134] Effects of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT Interval.

*Hiroaki Okayasu¹, Norio Sugawara¹, Kumiko Fujii², Kazutaka Shimoda¹, Yuji Ozeki², Norio Yasui-Furukori¹ (1. Department of Psychiatry, Dokkyo Medical University, Tochigi, Japan, 2. Department of Psychiatry, Shiga University of Medical Science, Otsu, Japan)

[P135] Safety and Efficacy of KarXT in Patients with Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

*Kenneth Kramer¹, Stephen K Brannan¹, Colin Sauder ¹, Inder Kaul¹ (1. Karuna Therapeutics )

[P136] The effect of lurasidone on PANSS Marder 5 factors and individual items in patients with acute schizophrenia: A post-hoc analysis of randomized, placebo-controlled trial (JEWEL study)

*Kentaro Takai¹, Itaru Miura², Shunji Toya¹, Fumiya Sano¹, Masaomi Iyo³ (1. Sumitomo Pharma Co., Ltd., Tokyo, Japan, 2. Fukushima Medical University, Fukushima, Japan, 3. Chiba University Graduate School of Medicine, Chiba, Japan)

[P137] Treatment persistence of paliperidone palmitate 3-month in patients with schizophrenia -an analysis of Japan Medical Data Center Claims Database

*Madoka Chinen¹, Yosuke Saga¹, Hiroshi Horio¹, Chih-Lin Chiang¹, Akihide Wakamatsu¹ (1. Medical Affairs Division, Janssen Pharmaceutical K.K.)

[P138] Associations of clozapine available institution and the diagnosis of subgroups about treatment-resistant schizophrenia or not with a higher rate of antipsychotic monotherapy and lower other concomitant psychotropics in overall schizophrenia treatment: A real-world nationwide study.

*Shinichiro Ochi¹, Fumitoshi Kodaka², Naomi Hasegawa³, Jun-ichi Iga¹, Hiroko Kashiwagi³, Hiroshi Komatsu⁴, Hiromi Tagata⁵, Takashi Tsuboi⁶, Shusuke Numata⁷, Hitoshi Iida⁸, Shun Igarashi⁶, Kazutaka Ohi⁹, Kentaro Fukumoto¹⁰, Hiroyuki Muraoka¹¹, Junya Matsumoto³, Kenichiro Miura³, Shu-ichi Ueno¹, Koichiro Watanabe⁶, Ken Inada¹¹, Ryota Hashimoto³, Norio Yasui-Furukori¹² (1. Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, Japan, 2. Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan, 3. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 4. Department of Psychiatry, Tohoku University Hospital, Miyagi, Japan, 5. Department of Neuropsychiatry, Toho University School of Medicine, Tokyo Japan, 6. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan, 7. Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan, 8. Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 9. Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan, 10. Department of Neuropsychiatry, School of Medicine, Iwate Medical University, Iwate, Japan, 11. Department of Psychiatry, Kitasato University, School of Medicine, Kanagawa, Japan, 12. Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan)

[P139] Prolactin level changes according to atypical antipsychotics use

*Jong-Hyun Jeong¹, Inki Sohn², Suhyung Kim¹, Yoo Hyun Um¹, Tae Won Kim¹, Ho-Jun Seo¹ (1. Department of Psychiatry, St. Vincent's Hospital, The Catholic University of Korea, 2. Department of Psychiatry, Keyo Hospital)

[P140] Clinical benefit and utility of Aripiprazole once Monthly in routine Practice for Korean schizophrenia patients (CAMP)

*Jiwan Moon¹, Hyeryun Yang¹, Eun soo Kim¹, Sang-Won Jeon^1,2, Young-Chul Shin¹, Sung Joon Cho^1,2 (1. Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, 2. Workplace Mental Health Institute, Kangbuk Samsung Hospital, Seoul, Korea)

[P141] Berberine reduces antipsychotic-associated weight gain in schizophrenia patients with low-level LDL: a pooled analysis of randomized controlled trial

*Zongshi Qin^1,2, Jiani Wu³ (1. School of Public Health, Peking University, 2. Peking University Clinical Research Institute, 3. Guang'anmen Hospital, China Academy of Chinese Medical Sciences)

[P142] A Case Report of Clozapine-Induced Myocarditis in a 27-Year-Old Schizophrenia Patient

*Jaisung NOH¹, HanKyel Ryu¹ (1. Department of Psyciatry, Ajou University. School of Medicine, Suwon Korea)

[P143] Antipsychotic medications and risk of all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study

*Chian-Jue Kuo^1,2,3, Wen-Yin Chen^1,4, Pao-Huan Chen^2,3, Shang-Ying Tsai^2,3, Chiao-Chicy Chen^2,3,5,6 (1. Taipei City Psychiatric Center, Taipei City Hospital, 2. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 3. Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan, 4. School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, 5. Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan, 6. Department of Psychiatry, Mackay Medical College, Taipei, Taiwan)

[P144] Identification of predictors for antipsychotic-induced weight gain: a nationwide cohort study

*Shuhei Ishikawa¹, Naoki Hashimoto², Ryo Okubo³, Ichiro Kusumi² (1. Department of Psychiatry, Hokkaido University Hospital, 2. Department of Psychiatry, Hokkaido University Graduate School of Medicine, 3. Department of Psychiatry and Neurology, National Hospital Organization Obihiro Hospital)

[P145] Interactive modulation of NMDAR and Oxidative Stress for the Treatment of Mental Disorders

*Hsien-Yuan Lane^1,2 (1. Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan, 2. Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan)

[P146] Antipsychotics and Mortality in Patients and Elderly Patients with Schizophrenia: A Nationwide Cohort Study in Taiwan

*WEI-CHEN LEE¹, Ling-Ling Yeh², Yi-Ju Pan^1,3 (1. Department of Psychiatry, Far Eastern Memorial Hospital, New Taipei City, Taiwan, 2. Graduate School of Humanities and Social Sciences, Dharma Drum Institute of Liberal Arts, New Taipei City, Taiwan, 3. Department of Chemical Engineering and Materials Science, Yuan Ze University, Taoyuan City, Taiwan)

[P147] Change of prescription for patients with schizophrenia during admission: Real-world prescribing surveys from the Effectiveness of Guidelines for Dissemination and Education psychiatric treatment project

*Naoki Hashimoto¹, Norio Yasui-Furukori², Naomi Hasegawa³, Hikaru Hori⁴, Hitoshi Iida⁴, Kayo Ichihashi⁵, Kenichiro Miura³, Junya Matsumoto³, Shusuke Numata⁶, Fumitoshi Kodaka⁷, Ryuji Furihata⁸, Ken Inada⁹, Koichiro Watanabe¹⁰, Ryota Hashimoto³ (1. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, 2. Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan, 3. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 4. Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 5. Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan, 6. Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan, 7. Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan, 8. Agency for Student Support and Disability Resources, Kyoto University, Kyoto, Japan, 9. Department of Psychiatry, Kitasato University School of Medicine, Kanagawa, Japan, 10. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan)

[P148] Polymorphism of the DRD2 gene and its potential influence on PANSS scores in patients with schizophrenia: A study conducted in South Sumatra, Indonesia.

*Bintang Arroyantri Prananjaya¹, Miranti Dwi Hartanti², Ziske Maritska Maritska³, Mgs Irsan Saleh Hasani⁴ (1. Department of Psychiatry, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia, 2. Department of Pharmacology, Faculty of Medicine, Universitas Muhammadiyah Palembang, Palembang, Indonesia, 3. Department of Biology Medicine, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia, 4. Department of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia)

[P149] Genome-wide DNA methylation risk scores for schizophrenia derived from blood and brain tissues further explain the genetic risk in patients stratified by polygenic risk scores for schizophrenia and bipolar disorder

*Kazutaka Ohi^1,2, Mihoko Shimada³, Midori Soda⁴, Daisuke Nishizawa⁵, Daisuke Fujikane¹, Kentaro Takai¹, Ayumi Kuramitsu¹, Yukimasa Muto¹, Shunsuke Sugiyama¹, Junko Hasegawa⁵, Kiyoyuki Kitaichi⁴, Kazutaka Ikeda⁵, Toshiki Shioiri¹ (1. Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan, 2. Department of General Internal Medicine, Kanazawa Medical University, Ishikawa, Japan, 3. Genome Medical Science Project (Toyama), National Center for Global Health and Medicine (NCGM), Tokyo, Japan, 4. Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan, 5. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan)

[P151] Association Between Allostatic Load and Cardiac Structure in Adult Patients With Schizophrenia

*Pao-Huan Chen^1,2, Shang-Ying Tsai^1,2, Cheng-Yi Hsiao^3,4 (1. Department of Psychiatry, Taipei Medical University Hospital, 2. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, 3. Division of Cardiology, Department of Internal Medicine, Taipei Medical University Hospital, 4. Taipei Heart Institute, Taipei Medical University)

[P256] Rapid titration influencing a late onset clozapine-induced myocarditis in a low-resource country setting: An Indonesian case report and narrative review

*Lee Thung Sen¹, Enjeline Hanafi¹, Khamelia Khamelia¹, Kristiana Siste¹ (1. dr. Cipto Mangunkusumo National Referral General Hospital - Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia)

[P512] Is there an Optimal Electrode Placement for Patients with Schizophrenia undergoing Electroconvulsive Therapy?

*Weng Jun Tan¹, Jenies Hui Xin Foo¹, Kimberly Wan Xin Choo¹, Phern Chern Tor¹ (1. Institute of Mental Health, Singapore )

Session information

Schizophrenia 1 - Clinical (1)